RHUMBLINE ADVISERS - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 205 filers reported holding BRIDGEBIO PHARMA INC in Q1 2021. The put-call ratio across all filers is 1.92 and the average weighting 0.8%.

Quarter-by-quarter ownership
RHUMBLINE ADVISERS ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q3 2023$4,740,229
+55.0%
179,759
+1.1%
0.01%
+100.0%
Q2 2023$3,058,762
+113524.1%
177,835
+9.5%
0.00%0.0%
Q1 2023$2,692
+123.8%
162,387
+2.8%
0.00%
+50.0%
Q4 2022$1,203
-99.9%
157,939
+3.7%
0.00%0.0%
Q3 2022$1,514,000
+18.3%
152,304
+8.0%
0.00%0.0%
Q2 2022$1,280,000
+2.2%
141,011
+14.2%
0.00%0.0%
Q1 2022$1,253,000
-41.0%
123,491
-3.0%
0.00%
-33.3%
Q4 2021$2,124,000
-64.7%
127,332
-0.7%
0.00%
-62.5%
Q3 2021$6,010,000
-22.0%
128,231
+1.4%
0.01%
-20.0%
Q2 2021$7,710,000
+20.9%
126,476
+22.2%
0.01%
+11.1%
Q1 2021$6,377,000
-2.5%
103,519
+12.5%
0.01%0.0%
Q4 2020$6,542,000
+90.7%
91,994
+0.6%
0.01%
+80.0%
Q3 2020$3,430,000
-7.1%
91,417
-19.3%
0.01%
-16.7%
Q2 2020$3,692,000
+21.0%
113,232
+7.6%
0.01%0.0%
Q1 2020$3,052,000
+208.6%
105,246
+272.8%
0.01%
+200.0%
Q4 2019$989,000
+87.7%
28,228
+15.1%
0.00%
+100.0%
Q3 2019$527,00024,5320.00%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q1 2021
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$55,099,00039.31%
M28 Capital Management LP 466,200$4,233,0004.74%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$282,034,0003.75%
Octagon Capital Advisors LP 933,743$8,478,0002.26%
VIKING GLOBAL INVESTORS LP 26,620,991$241,719,0001.11%
HHLR ADVISORS, LTD. 5,362,014$48,687,0001.04%
Cormorant Asset Management, LP 1,469,179$13,340,0001.01%
Knott David M Jr 213,206$1,936,0000.81%
Fernwood Investment Management, LLC 183,900$1,670,0000.72%
HighVista Strategies LLC 105,942$962,0000.58%
View complete list of BRIDGEBIO PHARMA INC shareholders